Metraipolis › archive › dc_015eb901e2ca

Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney… — Europe PMC PMID:41303244

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41303244
DOI: 10.3390/jcm14228209
License (as archived): solo-consultazione
Archived: 2026-11-08T11:00:42.174Z
SHA-256 of the archived text: 3dd08686b2eaccaee444cf528b30371af426d0b67f09f4eb4f3d8f5cd8e02240
Stable URL of this page: https://metraipolis.com/documento/dc_015eb901e2ca

How to cite

Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney… — Europe PMC PMID:41303244 — Europe PMC (en), https://europepmc.org/article/MED/41303244 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_015eb901e2ca (Metraipolis archive dc_015eb901e2ca, sha256 3dd08686b2eaccaee444cf528b30371af426d0b67f09f4eb4f3d8f5cd8e02240)

BibTeX

@misc{dc015eb901e2ca,
  title = {Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney… — Europe PMC PMID:41303244},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41303244},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_015eb901e2ca; sha256 3dd08686b2eaccaee444cf528b30371af426d0b67f09f4eb4f3d8f5cd8e02240},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41303244. Agents can read the archived copy with the MCP tool read_document.